Tissue-specific micrornas and compositions and uses thereof

Abstract

The invention provides for isolated nucleic acid sequences of newly discovered micro RNAs that have been identified to exist in normal Human B cells and/or in tumor-related Human B cells, using an integrated bioinformatics method and pipeline described herein.

1 . An isolated nucleotide sequence
 consisting of from about 14 to about 31 nucleotides in length;   and   consisting essentially of a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1-130 and 1094, wherein the nucleotide sequence is about 97%, about 98%, or about 99% identical to a nucleic acid sequence comprising any one of SEQ ID NOS: 1-130 and 1094.   
     
     
         2 . An isolated nucleotide sequence
 consisting of from about 14 to about 31 nucleotides in length;   and   consisting essentially of a nucleotide sequence selected from the group consisting of SEQ ID NOS: 131-401, wherein the nucleotide sequence is about 97%, about 98%, or about 99% identical to a nucleic acid sequence having a SEQ ID NO: 131-401, and wherein the nucleotide sequence is not SEQ ID NO: 236.   
     
     
         3 . An isolated nucleotide sequence that is complementary to a nucleotide sequence of  claim 1  or  2 . 
     
     
         4 . An isolated nucleotide sequence that is complementary to all but 1, 2, 3, 4, or 5 nucleotides of the nucleotide sequence of  claim 1  or  2 . 
     
     
         5 . The nucleotide sequence of  claim 3 , wherein the nucleotide sequence is complementary to at least 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31 contiguous nucleotides of the nucleotide sequence of  claim 1 . 
     
     
         6 . The nucleotide sequence of  claim 3 , wherein the nucleotide sequence is complementary to at least 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31 contiguous nucleotides of the nucleotide sequence of  claim 2 . 
     
     
         7 . The nucleotide sequence of  claim 1  or  2 , wherein the nucleotide sequence is single stranded. 
     
     
         8 . The nucleotide sequence of  claim 3 , wherein the nucleotide sequence is single stranded. 
     
     
         9 . The nucleotide sequence of  claim 4 , wherein the nucleotide sequence is single stranded. 
     
     
         10 . The nucleotide sequence of  claim 1  or  2 , wherein the nucleotide sequence is double stranded. 
     
     
         11 . The nucleotide sequence of  claim 3 , wherein the nucleotide sequence is double stranded. 
     
     
         12 . The nucleotide sequence of  claim 4 , wherein the nucleotide sequence is double stranded. 
     
     
         13 . The acid nucleotide sequence of  claim 1  or  2 , wherein the nucleotide sequence is expressed in a lymphocyte. 
     
     
         14 . The nucleotide sequence of  claim 1  or  2 , wherein the nucleotide sequence is expressed in a B cell. 
     
     
         15 . The nucleotide sequence of  claim 14 , wherein the B cell comprises a Naïve B cell, a centroblast, a memory B cell, or a Ramos Burkitt Lymphoma cell. 
     
     
         16 . A composition comprising one or more nucleotide sequences of  claim 1 ,  2 ,  3 , or  4 , in any combination or permutation thereof. 
     
     
         17 . A composition comprising one or more nucleotide sequences, wherein the one or more nucleotide sequences consist essentially of a nucleotide sequence of any one of SEQ ID NOS: 1-401 and 1094, and wherein the nucleotide sequence is not SEQ ID NO: 236. 
     
     
         18 . The composition of  claim 16 , further comprising one or more carriers, excipients, solvents, bases, or a combination thereof. 
     
     
         19 . The composition of  claim 17 , further comprising one or more carriers, excipients, solvents, bases, or a combination thereof. 
     
     
         20 . A method for modulating the activity of a target nucleic acid in a cell, the method comprising contacting a cell with a nucleotide sequence of  claim 1 ,  2 ,  3 , or  4 . 
     
     
         21 . The method of  claim 20 , wherein the target nucleic acid is a mRNA, a mature miRNA, or a precursor to a mature miRNA. 
     
     
         22 . The method of  claim 20 , wherein the cell is a hematopoetic cell. 
     
     
         23 . The method of  claim 20 , wherein the cell is a B cell. 
     
     
         24 . The method of  claim 20 , wherein the cell is in vitro or in vivo.